Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

C-reactive protein (CRP)-lowering agents.

Kailash Prasad1

  • 1Department of Physiology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. prasadk@usask.ca

Cardiovascular Drug Reviews
|August 31, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of C-Reactive Protein, An Inflammatory Biomarker in The Development of Atherosclerosis and Its Treatment.

The International journal of angiology : official publication of the International College of Angiology, Inc·2024
Same author

Atherogenic Effect of Homocysteine, a Biomarker of Inflammation and Its Treatment.

The International journal of angiology : official publication of the International College of Angiology, Inc·2024
Same author

Mechanism of Hypercholesterolemia-Induced Atherosclerosis.

Reviews in cardiovascular medicine·2024
Same author

Clinical features of early-onset pediatric traumatic glaucoma and predictive factors for the need of early glaucoma surgery.

Indian journal of ophthalmology·2023
Same author

Involvement of AGE and Its Receptors in the Pathogenesis of Hypertension in Elderly People and Its Treatment.

The International journal of angiology : official publication of the International College of Angiology, Inc·2023
Same author

Does AGE-RAGE Stress Play a Role in the Development of Coronary Artery Disease in Obesity?

The International journal of angiology : official publication of the International College of Angiology, Inc·2022

Many cardiovascular drugs, including statins, ACE inhibitors, and ARBs, effectively lower C-reactive protein (CRP) levels. These reductions may contribute to improved cardiovascular outcomes, highlighting CRP

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • C-reactive protein (CRP) is a key marker and predictor of cardiovascular disease (CVD).
  • CRP contributes to CVD pathogenesis through various mechanisms like promoting clotting and plaque destabilization.
  • Understanding drug effects on CRP is crucial for managing cardiovascular health.

Purpose of the Study:

  • To review the impact of diverse cardiovascular medications on C-reactive protein (CRP) levels.
  • To assess how different drug classes influence CRP in both healthy individuals and those with cardiovascular disease.

Main Methods:

  • Systematic review of existing literature on cardiovascular drugs and their effect on CRP levels.
  • Analysis of studies examining drug-induced changes in serum or plasma CRP concentrations.

Related Experiment Videos

  • Categorization of drugs based on their observed effects (reduction, no effect, variable effect) on CRP.

    • Main Results:

    • Cyclooxygenase inhibitors, platelet aggregation inhibitors, statins, ACE inhibitors, angiotensin receptor blockers (ARBs), and certain antidiabetic agents significantly reduce CRP levels.
    • Specific drugs like enalapril and trandolapril did not demonstrate CRP-lowering effects, while ARBs (except losartan and candesartan) showed marked reduction.
    • Statins' CRP-lowering effect is pronounced and independent of lipid reduction; vitamin E and beta-blockers also lower CRP, whereas hydrochlorothiazide and oral estrogen do not.

    Conclusions:

    • Several cardiovascular drug classes, including lipid-lowering agents, ACE inhibitors, ARBs, and anti-inflammatory drugs, effectively lower CRP.
    • The CRP-lowering capacity of certain medications, notably statins, likely contributes to their therapeutic benefits in cardiovascular disease.
    • Further research may elucidate the clinical significance of CRP modulation by various cardiovascular therapies.